Literature DB >> 33531264

Dynamic changes in monocytes subsets in COVID-19 patients.

Shuang Qin1, Yujie Jiang1, Xin Wei2, Xiaoyuan Liu3, Jingjing Guan1, Yingxiao Chen4, Hong Lu1, Jingjing Qian1, Zhongyong Wang5, Xiangyang Lin6.   

Abstract

BACKGROUND: Coronavirus disease 2019 (COVID-19) is affecting the whole world and threatening human health. We aim to investigate the immunological characteristics of monocytes in critical patients with COVID-19.
METHODS: The number and immune status of monocytes were detected by flow cytometry in 32 COVID-19 patients and 18 healthy individuals.
RESULTS: In critical patients with COVID-19, the absolute number of total monocytes and CD16- monocytes was significantly decreased but CD16+ pro-inflammatory monocytes was increased compared to healthy controls. Antigen presentation potential of monocytes, as measured by HLA-DR expression, was suppressed, while their inflammatory phenotype (CD38 expression) was enhanced. Cytokine levels showed sustained increases in critical patients. And the levels of IL-6 were positively correlated with CD16+ monocytes number. IL-6 and IL-10 levels were negatively correlated with HLA-DR expression of monocytes. During the recovery of COVID-19 patients, the count and immune status of monocyte subsets were restored by degrees. HLA-DR+ monocytes possessed good sensitivity and specificity for predicting the incidence of critical patients with COVID-19.
CONCLUSIONS: In critical patients with COVID-19, decline in number and HLA-DR expression of monocytes might lead to decreased antigen presentation potential and thus immunosuppression, while increased CD16+ pro-inflammatory monocytes might mediate hyperinflammation. HLA-DR+ monocytes might be a meaningful assisted indicator to predict the incidence of critical patients with COVID-19.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Antigen presentation; COVID-19; Hyperinflammation; Monocytes

Year:  2020        PMID: 33531264     DOI: 10.1016/j.humimm.2020.12.010

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  13 in total

1.  Low levels of the key B cell activation marker, HLA-DR, in COVID-19 hospitalized cases are associated with disease severity, dexamethasone treatment, and circulating IL-6 levels.

Authors:  Anthony Dobi; Arthur Dubernet; Mahary Lalarizo Rakoto; Anne-Laure Sandenon Seteyen; Damien Vagner; Grégorie Lebeau; Loïc Raffray; Philippe Gasque
Journal:  Immunol Res       Date:  2022-06-09       Impact factor: 4.505

2.  Intermediate Monocytes with PD-L1 and CD62L Expression as a Possible Player in Active SARS-CoV-2 Infection.

Authors:  Elżbieta Rutkowska; Iwona Kwiecień; Krzysztof Kłos; Piotr Rzepecki; Andrzej Chciałowski
Journal:  Viruses       Date:  2022-04-15       Impact factor: 5.818

Review 3.  Pathological effects of SARS-CoV-2 on hematological and immunological cells: Alterations in count, morphology, and function.

Authors:  Ehsan Ahmadi; Zahra Bagherpour; Elmira Zarei; Azadeh Omidkhoda
Journal:  Pathol Res Pract       Date:  2022-01-29       Impact factor: 3.250

Review 4.  The molecular mechanism of SARS-CoV-2 evading host antiviral innate immunity.

Authors:  Wenjing Gu; Hui Gan; Yu Ma; Lina Xu; Zhangkai J Cheng; Bizhou Li; Xinxing Zhang; Wujun Jiang; Jinlv Sun; Baoqing Sun; Chuangli Hao
Journal:  Virol J       Date:  2022-03-19       Impact factor: 4.099

5.  Reduced Absolute Count of Monocytes in Patients Carrying Hematological Neoplasms and SARS-CoV2 Infection.

Authors:  Alessandra Romano; Claudio Cerchione; Concetta Conticello; Sabina Filetti; Anna Bulla; Annalisa Chiarenza; Vittorio Del Fabro; Salvatore Leotta; Uros Markovic; Giovanna Motta; Marina Parisi; Fabio Stagno; Giuseppe Alberto Palumbo; Francesco Di Raimondo
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

Review 6.  Trained Immunity: An Overview and the Impact on COVID-19.

Authors:  Justin M Brueggeman; Juan Zhao; Madison Schank; Zhi Q Yao; Jonathan P Moorman
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

7.  Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review.

Authors:  David Andaluz-Ojeda; Pablo Vidal-Cortes; Álvaro Aparisi Sanz; Borja Suberviola; Lorena Del Río Carbajo; Leonor Nogales Martín; Estefanía Prol Silva; Jorge Nieto Del Olmo; José Barberán; Ivan Cusacovich
Journal:  World J Crit Care Med       Date:  2022-07-09

8.  The efficacy of combined therapy of qingfeiPaidu capsule and lianhuaqingwen capsule nursing interventions for hospitalized patients with COVID-19: A retrospective study of medical records.

Authors:  Yan Li; Wenhan Yu; Jinxia Zhai; Kun Wang; Hongdan Huo; Zonghua Du
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

9.  Clinical Characteristics and Survival Analysis in Frequent Alcohol Consumers With COVID-19.

Authors:  Ricardo Wesley Alberca; Paula Ordonhez Rigato; Yasmim Álefe Leuzzi Ramos; Franciane Mouradian Emidio Teixeira; Anna Cláudia Calvielli Branco; Iara Grigoletto Fernandes; Anna Julia Pietrobon; Alberto Jose da Silva Duarte; Valeria Aoki; Raquel Leão Orfali; Maria Notomi Sato
Journal:  Front Nutr       Date:  2021-06-02

Review 10.  SARS-CoV-2 Variants, Vaccines, and Host Immunity.

Authors:  Priyal Mistry; Fatima Barmania; Juanita Mellet; Kimberly Peta; Adéle Strydom; Ignatius M Viljoen; William James; Siamon Gordon; Michael S Pepper
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.